ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Prednisolone

Also written as “Desloratadine + Prednisolone”, “prednisolone” and “Desloratadine , Prednisolone”.

Its studies are mostly in Prostatic Neoplasms · Arthritis, Rheumatoid · Rhinitis, Allergic · Asthma · Pulmonary Disease, Chronic Obstructive, led by 13 companies.

Drug pagePrednisolone: every studyMany companies study it; this page follows only the 26 they lead. All 247 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 11, 201026 company-led studies, 2 open or runningNext primary completion: Oct 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only50 open or runningphase 3since Mar 11, 2010Aug 24, 2005none ahead
Sanofiits history only50 open or runningphase 4since Feb 26, 2014Jul 9, 2007none ahead
EMSits history only40 open or runningphase 3since Sep 5, 2011Sep 5, 2011none ahead
Astellas Pharmaits history only32 open or runningphase 2since May 27, 2025Jun 26, 2024Oct 31, 2027phase 2 · NCT07052929
Adapt Produtos Oftalmológicos Ltda.its history only10 open or runningphase 3since Mar 22, 2011Mar 22, 2011none ahead
Bausch Health Companiesits history only10 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
Biogenits history only10 open or runningphase 4since Jul 29, 2010Jul 29, 2010none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 4since Jan 3, 2019Jan 3, 2019none ahead
Eurofarma Laboratoriosits history only10 open or runningphase 3since Dec 13, 2021Dec 13, 2021none ahead
Hamad Medicalits history only10 open or runningphase 3since Nov 7, 2012Nov 7, 2012none ahead
Hoffmann-La Roche10 open or runningphase 2since Sep 6, 2013Sep 6, 2013none ahead

Also a collaborator on its studies: Elan Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 6, 2013First study: phase 2 study in AsthmaFirst studyNCT01948401 · 54 enrolled · United Kingdom

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01948401Asthma · United Kingdom2CompletedApr 201454

How it is read

Names in the registry

  • “Prednisolone”, 17 entries
  • “Desloratadine + Prednisolone”, 3 entries
  • “prednisolone”, 3 entries
  • “Desloratadine , Prednisolone”, 1 entry
  • “Oral prednisolone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.